Long-Term European Results Highlight the Importance of This Study for U.S.

EDAP Ablatherm-HIFU Presents at American Urology Association Accelerates US Study Enrollment LYON, France , May 23 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, reports the continuing advancement

EDAP Looking to Accelerate US Study Enrollment With the Upcoming Addition of McMaster University Hospital LYON, France , June 1 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, reports further

EDAP to Add University of Colorado Under Direction of Dr. David Crawford to Clinical Study LYON, France , June 5 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, intends to add the University of

EDAP Ablatherm-HIFU Strongly Highlighted in European Congresses LYON, France , June 18 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, reports continued and sustained marketing presence in various

First UK Fixed Revenue-Per-Procedure Service Available at Capio Springfield Hospital

EDAP Adds Malaysia, Korea to France as Exclusive Markets and Secures Worldwide Exclusivity When StoneBreaker™ Offered with EDAP's Devices

Official Report Ranks Ablatherm-HIFU User Sites Among Top French Public Hospitals

Strong North American Focus, Expertise to Augment US Study Program

Dedicated Press Conference Organized at Edouard Herriot Hospital, Lyon, France